The efficacy of XXXX therapy after extracorporeal shock-wave lithotripsy for ureteric calculi: A prospective randomised, controlled study.

@entity1 @entity9940 @entity3522
OBJECTIVE: To evaluate whether @entity9940 is effective as an adjunctive medical therapy to increase the effectiveness of extracorporeal shock-wave lithotripsy (ESWL) for treating ureteric stones, and minimises the use of analgesic drugs after the procedure. @entity1 AND METHODS: To treat single ureteric stones of 5-15  mm in diameter, 130 @entity1 were treated with ESWL. After treatment, equal numbers of @entity1 were randomly assigned to receive either the standard medical therapy alone (controls) or combined with 0.4  mg @entity9940 daily for    12  weeks. All @entity1 were followed up for 3  months or until an alternative treatment was offered. RESULTS: At 3  months the treatment was considered to be clinically successful in 55/65 (85%) of those receiving @entity9940 and in 58/65 (89%) of the controls (P  =  0.34). When @entity1 were classified according to stone size the success rate was similar in both groups (P  =  0.22) for those with a stone of >10  mm. However, ureteric colic was reported in 12% of @entity1 treated with standard therapy but in only 5% of those treated with @entity9940 (P  =  0.006). The mean cumulative @entity3522 dose was 380  mg/ @entity1 in the @entity9940 group and 750  mg/ @entity1 in the control group (P  =  0.004). CONCLUSIONS: This study showed the effectiveness of @entity9940 as an adjunctive medical therapy after ESWL for ureteric stones, but it did not improve stone clearance when treating ureteric stones. However, it decreased the use of analgesics and reduced the complication rate, especially for steinstrasse.
